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Abstract
Until recently, matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) techniques for the
identiﬁcation of microorganisms remained conﬁned to research laboratories. In the last 2 years, the availability of relatively simple to use
MALDI-TOF MS devices, which can be utilized in clinical microbiology laboratories, has changed the laboratory workﬂows for the
identiﬁcation of pathogens. Recently, the ﬁrst prospective studies regarding the performance in routine bacterial identiﬁcation showed that
MALDI-TOF MS is a fast, reliable and cost-effective technique that has the potential to replace and/or complement conventional
phenotypic identiﬁcation for most bacterial strains isolated in clinical microbiology laboratories. For routine bacterial isolates, correct
identiﬁcation by MALDI-TOF MS at the species level was obtained in 84.1–93.6% of instances. In one of these studies, a protein extraction
step clearly improved the overall valid identiﬁcation yield, from 70.3% to 93.2%. This review focuses on the current state of use of
MALDI-TOF MS for the identiﬁcation of routine bacterial isolates and on the main difﬁculties that may lead to erroneous or doubtful
identiﬁcations.
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Introduction
In clinical microbiology laboratories, the identiﬁcation of
microorganisms in patient samples has long been mainly
based on the detection of phenotypic characteristics
exhibited by the putative pathogens. Gram stain, colony
morphology, microscopic examination, differential growth on
selective media and various biochemical tests, with
either manual or automated methods, form the mainstay of
the classiﬁcation of bacteria, yeast and fungi. Because
these methods often rely on active metabolic processes of
the involved microorganisms, growth and therefore long
incubation periods are sometimes needed. Molecular
diagnostic methods, mainly 16S ribosomal RNA sequencing
or real-time PCR detection of selected genes, have been
used as alternative approaches, but these techniques remain
complicated and costly, and are not suited for use on the
vast majority of routine samples that are commonly
processed each day in clinical microbiology laboratories.
The principles of the mass spectrometry technique have
been established for over a century, and the ﬁrst attempts at
using it for the characterization of intact microorganisms
were made in 1975 [1]. In the 1980s, the development of
soft ionization matrix-assisted laser desorption ionization
time-of-ﬂight mass spectrometry (MALDI-TOF MS) allowed
the analysis of relatively large biomarkers [2,3]. Subsequently,
a few other studies assessed the feasibility of MALDI-
TOF MS identiﬁcation for various bacterial species (e.g. [4–
9]). However, it is only very recently that relatively simple
to use MALDI-TOF MS devices have become available for
utilization by non-mass spectrometry specialists in a routine
setting. This review describes the present state of use of
MALDI-TOF MS for isolates that are commonly encountered
in clinical microbiology laboratories, and presents the main
causes of erroneous or doubtful identiﬁcations.
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Use of MALDI-TOF MS in Clinical
Microbiology Settings
Implementation of a MALDI-TOF MS device in a clinical
microbiology laboratory
Commercially available MALDI-TOF MS devices intended for
use in clinical microbiology laboratories are the size of other
conventional automated devices commonly found in labora-
tories, and do not require speciﬁc equipment, apart from the
usual electrical and computer connections. Depending on the
manufacturer, various methods for connecting the MALDI-
TOF MS device to the laboratory information system and for
interfacing it with other automated devices are available or
under development. A chemical hood will be needed to per-
form a protein extraction step (based on a liquid solution of
acetonitrile and formic acid in water) when the direct depo-
sition of the sample on the target plate does not yield a valid
identiﬁcation result (Fig. 1).
Ease of use
In comparison with the identiﬁcation of clinical samples by con-
ventional methods (e.g. ‘home-made’ biochemical galleries, API
strips, Vitek automated instruments), and despite its high-end
technology, a MALDI-TOF MS device is simple to use. The mass
spectrometer mechanical interface usually consists of a small
trap allowing the introduction of a target plate on which the
samples are deposited, which opens and closes at the push of a
single button. The only learning step concerns the analysis soft-
ware, which mainly requires basic point and click operations.
In practice, apposition of samples on the target plates can
be performed either by touching the investigated colony with
a sterile pipette tip and directly applying a small amount of
sample onto the surface of the target plate, or by the depo-
sition of a protein solution when an extraction step has been
performed. Samples are then overlaid by a suitable matrix
(typically a saturated solution of a-cyano-4-hydroxycinnamic
acid in 50% acetonitrile and 2.5% triﬂuoroacetic acid) and
air-dried before being processed by the mass spectrometer.
It is of note that whereas the direct application of a colony
is performed in a matter of seconds, extraction of a sample
takes about 6 min (per-sample processing time can be
reduced by batch processing). In our experience, teaching
the use of MALDI-TOF MS to laboratory technician person-
nel, including the protein extraction procedure, requires only
about 1 h.
Performance of MALDI-TOF MS-based bacterial identiﬁca-
tion with routine samples
A retrospective study by Eigner et al. [10] on 1116 routine
isolates representing the main bacterial groups encountered
in the clinical microbiology laboratory showed 95.2% correct
identiﬁcation by MALDI-TOF MS. It is only very recently that
prospective studies aimed at assessing the performance of
MALDI-TOF MS identiﬁcation with routine samples have
been published (Table 1). Seng et al. [11] showed that of
1660 bacterial isolates representing 109 different species,
84.1% were correctly identiﬁed by MALDI-TOF MS at the
species level and 11.3% at the genus level only. According to
the authors, absent or erroneous identiﬁcations were attrib-
utable to improper MALDI-TOF software database entries
in only a limited number of cases, i.e. 2.8% and 1.7%,
respectively. Van Veen et al. [12] prospectively analysed
980 isolates, and found an overall concordance between
FIG. 1. Typical workﬂow of a matrix-assisted
laser desorption ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS) device used
in a clinical microbiology laboratory. It is of
note that multiple parallel direct depositions
or protein extractions for the same sample
might be performed in order to obtain a valid
result.
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MALDI-TOF MS and conventional methods of 92% at the
species level and 6.8% at the genus level. A study by Cherka-
oui et al. [13] compared two commercially available MALDI-
TOF MS systems (Bruker Daltonics and Shimadzu) for phe-
notypic bacterial identiﬁcation of 720 samples representing
33 different genera. In their setting, correct identiﬁcation at
the species level by MALDI-TOF MS was obtained in 93.6%
of cases for the Bruker and 88.3% for the Shimadzu. In a
study performed in our laboratory [14], we prospectively
analysed 1371 clinical isolates, and found that 1278 (93.2%)
were putatively identiﬁed at the species level by MALDI-
TOF MS, and 73 (5.3%) at the genus level; no reliable identi-
ﬁcation was obtained for 20 (1.5%). Among the 1278 valid
results, the identiﬁcation matched with conventional identiﬁ-
cation methods at the species level in 95.1% (1215), matched
at the genus level in 3% (39) and was discordant at the genus
and species level in 1.9% (24). Most discordant results (42/
63) were attributable to systematic database-related taxo-
nomic differences, 14 to poor discrimination of the MALDI-
TOF MS spectra obtained, and seven to errors in the initial
conventional identiﬁcation (Table 2).
Altogether, even though some improvements will be
required, in particular for the identiﬁcation of mitis and viri-
dans group streptococci as well as anaerobes [11,13,14],
these studies indicate that MALDI-TOF MS is an efﬁcient and
reliable method for the identiﬁcation of bacteria from clinical
samples.
Cost-effectiveness
In their study, Seng et al. [11] estimated the cost of MALDI-
TOF MS identiﬁcation (including consumables, salaries and
depreciation of the apparatus over 5 years) to be one-quar-
ter of that of conventional identiﬁcation (€2.44 with MALDI-
TOF MS vs. €4.60–13.85 with an automated identiﬁcation
system). The same cost reduction was estimated by
Cherkaoui et al. [13]. We have observed that other aspects
of MALDI-TOF MS-based identiﬁcation reduce identiﬁcation-
related costs. First, as MALDI-TOF MS requires only minute
amounts of material (typically a fraction of a microorganism
colony) to yield an identiﬁcation, there is no need to inocu-
late multiple growth plates in order to obtain a sufﬁcient
inoculum, as is required with various automated phenotypic
TABLE 1. Performance of matrix-assisted laser desorption ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS)
identiﬁcation with routine samples in clinical microbiology laboratories
Number of
isolates tested
Manufacturer of
the MALDI-TOF
MS system
Overall correct
identiﬁcation at the
species level (%)
Overall correct
identiﬁcation at
the genus level (%)
Correct identiﬁcation of
Gram-negative bacteria
at the species level (%)
Correct identiﬁcation of
Gram-positive bacteria
at the species level (%) References
1660a Bruker Daltonics GmbH 84.1 11.3 NA NA [11]
1371a Bruker Daltonics GmbH 91.7 2.8 88.8 88.0 [14]
720a Bruker Daltonics GmbH 93.6 NA 98.2 83.9 [13]
720a Shimadzu Corporation 88.3 NA 94.8 75.6 [13]
1116b Bruker Daltonics GmbH 95.2 4.8 93.8 97.7 [10]
NA, not available.
aProspective study.
bRetrospective study.
TABLE 2. Examples of discordant results between conventional and matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS) identiﬁcation
Conventional ID MALDI-TOF MS ID 16S rDNA sequencing ID Explanation References
Enterobacter cloacae Enterobacter hormaechei E. hormaechei Conventional methods such as Vitek 2 system
(BioMe´rieux) do not identify some species of
the E. cloacae complex group
[14]
Stenotrophomonas maltophilia
S. maltophilia
Pseudomonas hibiscicola
Pseudomonas beteli
S. maltophilia
S. maltophilia
Invalid taxonomic name (heterotypic synonyms of
S. maltophilia that should not be used according to
the recent taxonomy)
[10,11,14]
Shigella sonnei
Shigella ﬂexneri
Streptococcus pneumoniae
Streptococcus mitis
Escherichia coli
Escherichia coli
Streptococcus parasanguinis
Streptococcus pneumoniae
Shigella sonnei
Shigella ﬂexneri
Streptococcus pneumoniae
Streptococcus mitis
Absence of enough reference spectra in the
MALDI-TOF MS database, leading to insufﬁcient
discriminative power for closely related species
[10,11,14]
Propionibacterium acnes Eubacterium brachy P. acnes Incorrect reference spectra in the MALDI-TOF MS
database
[14]
Streptococcus dysgalactiae Streptococcus pyogenes or
Streptococcus dysgalactiae
on repeated independent
deposits
Streptococcus dysgalactiae Inconsistent results, owing either to difﬁcult-to-
differentiate strains or a lack of sufﬁcient reference
spectra in the MALDI-TOF MS database
[14]
ID, identiﬁcation.
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methods. Second, the high number of subcultures of samples
on multiple media under various atmosphere conditions, as
is the case, for example, for the identiﬁcation of anaerobic
ﬂora, is dramatically decreased. Taken together, these small
but deﬁnite improvements in workﬂow also reduce both
laboratory technician hands-on time and material costs.
Speed
Regarding speed of identiﬁcation, Seng et al. [11] estimated a
mean time to result for samples identiﬁed by MALDI-TOF MS
of 6 min, whereas conventional techniques would yield the
same identiﬁcations in 5–48 h. Further studies will be required
in various settings to assess the impact of faster result deter-
mination on patient treatment outcomes, in particular because
identiﬁcation is often only a part of the microbiological pro-
cess, the other being antibiotic susceptibility testing. Neverthe-
less, the ability to obtain such a fast identiﬁcation of pathogens
can be used, together with local antibiotic resistance data, to
efﬁciently optimize early empirical antibiotic treatment.
Speciﬁc species studies
There is theoretically no limit to the identiﬁcation ability of
MALDI-TOF MS, as long as a suitable reference spectrum is
present in the database. Therefore, either by directly using
databases provided by the various manufacturers or by the
development of additional in-house, speciﬁc spectra databases,
a wide array of relevant pathogen species in clinical micro-
biology have been studied with MALDI-TOF MS. This
includes the identiﬁcation of 97.5% of 277 clinical isolates of
the Bacteroides genus [15] and 92.3% of 39 Bartonella species
(after the addition of 17 reference spectra in the MALDI-
TOF MS database) [16], and the identiﬁcation and typing of
Listeria, which showed complete concordance of pulsed-ﬁeld
gel electrophoresis with the MALDI-TOF MS-based group-
ings for Listeria monocytogenes [17]. Furthermore, after the
addition of further reference spectra to the database,
MALDI-TOF MS gave nearly 100% correct identiﬁcations
of Neisseria [18], clostridia [19], mycobacteria [20], non-
fermenters [21], Salmonella [22], viridans streptococci [23]
and Helicobacter pylori [24].
Yeasts, ﬁlamentous fungi and dermatophytes
MALDI-TOF MS has been used to characterize both yeasts
and ﬁlamentous fungal species. The databases of most com-
mercially available identiﬁcation software associated with a
MALDI-TOF MS device include reference spectra of the most
commonly encountered yeasts in the laboratory, such as Can-
dida albicans, Candida glabrata, Candida krusei, Candida tropicalis,
Candida parapsilosis and Cryptococcus neoformans. Marklein et al.
[25] showed that 96% of 250 clinical Candida isolates belonging
to 15 species were correctly identiﬁed by MALDI-TOF MS. In
prospective studies, Van Veen et al. and Bizzini et al. [12,14]
showed that MALDI-TOF MS yielded correct identiﬁcation of
85% of 61 isolates belonging to 12 different species and 100%
of 24 isolates belonging to four different species, respectively.
On the other hand, relatively few data are currently available
regarding the identiﬁcation of ﬁlamentous fungi. There are sev-
eral reasons for this situation. In contrast to bacteria, ﬁlamen-
tous fungi exhibit radically different phenotypes, and protein
spectra might depend on their growth conditions or the zone
of the fungal mycelium that is taken for analysis. Also, protein
extraction protocols for ﬁlamentous fungi lack standardiza-
tion. Moreover, very few reference spectra are currently
included in the database of commercially available devices.
Altogether, these factors contribute to the fact that, to the
best of our knowledge, no routine prospective study regarding
the identiﬁcation of fungi in the clinical microbiology setting
has yet been published. However, some recent studies have
shown the potential of the MALDI-TOF MS technique to iden-
tify fungal clinical fungi such as Aspergillus [26], Penicillium [27],
Fusarium [28] or various dermatophytes [29] (for a review,
see [30]). It is of note that these studies built and used their
own reference spectra database and were performed using
strictly controlled pre-analytical steps (such as culture medium
and duration of incubation). Further improvements in databas-
es and pre-analytical protocols will be required before the
identiﬁcation of ﬁlamentous fungi can be routinely performed
with MALDI-TOF MS-based devices.
Direct identiﬁcation of pathogens in samples
Because of the sensitivity of MALDI-TOF MS (104 CFU for
Escherichia coli), the direct identiﬁcation of pathogens in the
sample itself, without a culture step, has been tested in various
setting. Most noticeable are positive blood cultures (see the
review by M. Drancourt in this issue). In prospective studies,
using different protocols combining centrifugation steps, the
use of serum separator tubes or ammonium chloride lysis, La
Scola et al. [31], Prod’hom et al. [32] and Stevenson et al. [33]
showed that MALDI-TOF MS correctly identiﬁed 66% (91% of
the Gram-negative and 49% of the Gram-positive) of 562, 79%
(90% of the Gram-negative bacteria and 73% of the Gram-
positive bacteria) of 122 and 76.4% of 212 monomicrobial
positive blood cultures, respectively. It is of note that current
MALDI-TOF MS data software analysis is not able to reliably
identify all microorganisms present in mixed cultures [31–33].
Also, with the use of a concentration step, the direct
identiﬁcation of pathogens in urine samples has been shown
to be feasible (Borovskaya et al., 19th ECCMID, 2009,
Abstract P1065). However, whereas the rapid identiﬁcation
of organisms in blood cultures is now routinely performed
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by MALDI-TOF MS in our laboratory, MALDI-TOF MS does
not seem to be currently practical for urine samples, as a sig-
niﬁcant number of urine samples are currently simply pro-
cessed by a Gram stain followed by quantitative plating on
chromogenic media. The use of ﬂow cytometry in order to
eliminate negative samples might render downstream use of
MALDI-TOF MS more efﬁcient.
Search for antibiotic resistance determinants and virulence
factors, and antibiotic susceptibility testing
As it relies on various cell wall and proteome-related struc-
tural alterations of Staphylococcus aureus, some studies have
shown the ability of mass spectrometry to distinguish methi-
cillin-susceptible S. aureus from methicillin-resistant S. aureus
strains [7,34]. Because of its wide clinical and infection con-
trol implications, prospective studies are required to ascer-
tain the sensitivity of the method, which might, at least in
part, replace conventional oxacillin or cefoxitin disk suscepti-
bility testing in a ﬁrst approach. This might prove to be of
particular interest in the rapid identiﬁcation of methicillin-
resistant S. aureus in blood cultures.
The search for other predictive antibiotic resistance
determinants by MALDI-TOF MS will probably be of particu-
lar interest. Antibiotic resistance mechanisms relying on sub-
tle protein alterations (such as penicillin-binding protein
mutations conferring various degrees of b-latam resistance
or mutations in topoisomerase genes conferring quinolone
resistance), or inducible resistance mechanisms, will probably
be difﬁcult to assess by MALDI-TOF MS. On the other hand,
various acquired bacterial enzymes targeting antimicrobial
molecules (such as b-lactamases, methylases and efﬂux
pumps) might possibly be detected by MALDI-TOF MS.
Interestingly, a deﬁnitive ‘proteome shift’ in C. albicans, cor-
responding to its ﬂuconazole MIC measured by conventional
methods, proves that MALDI-TOF MS-based methods of
antibiotic susceptibility testing might be feasible [35].
With the use of unbiased bioinformatic approaches, MALDI-
TOF MS spectra can be analysed without a priori expectations
regarding the correlation of a virulence phenotype with spec-
tral characteristics. This is exempliﬁed by the appearance of a
4448 mass-to-charge ratio peak in S. aureus strains positive for
Panton–Valentine leukocidin, and the absence of such a peak in
Panton–Valentine leukocidin-negative S. aureus strains, with a
sensitivity of 100% and speciﬁcity of 90.6% [36].
Conclusions
Because of its speed, ease of use and low per-sample cost,
MALDI-TOF MS will undoubtedly radically change the
approach used by clinical microbiology laboratories for the
identiﬁcation of microorganisms. The use of phenotypic bio-
chemical tests, rapid agglutination kits or growth-based iden-
tiﬁcation methods, which are currently the routine methods
in laboratory identiﬁcation, will diminish, and they will be
replaced by workﬂows centred on MALDI-TOF MS as a ﬁrst
step in the identiﬁcation process. Molecular diagnostic tech-
niques such as eubacterial PCR will still be useful with difﬁ-
cult samples for which no microorganism growth can be
obtained, but 16S rRNA sequencing will only be required in
the few cases for which no reference spectra are present in
the MALDI-TOF MS databases at the time of analysis.
Currently, MALDI-TOF MS identiﬁcation still requires a
growth step in order to obtain bacterial colonies for acquisi-
tion of spectra, and it cannot reliably identify the presence of
several different pathogens in a sample. Therefore, apart
from positive blood cultures or urine specimens with a large
number of bacteria per millilitre, MALDI-TOF MS cannot
currently be used directly on patient samples. In that con-
text, the development of new enrichment techniques, such
as afﬁnity capture coupled to MALDI-TOF MS analysis, will
certainly be of particular interest [37,38], and may allow the
direct analysis of samples, even those containing numerous
species, such as respiratory tract or stool samples.
Also, apart from the identiﬁcation process, other aspects
of microorganism analysis, such as the search for virulence
factors and antibiotic resistance determinants, and typing, will
see a tremendous development. This, in combination with
the potential of each laboratory to create its own reference
spectra and to create interlaboratory databases, will be a
cornerstone of the extension of MALDI-TOF MS analysis in
clinical microbiology laboratories.
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